Prelude Therapeutics (PRLD) Total Current Liabilities (2019 - 2026)

Prelude Therapeutics has reported Total Current Liabilities for 8 years, with the latest figure at $41.7 million in Q1 2026.

• Quarterly Total Current Liabilities rose 110.85% year-over-year to $41.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.7 million (up 110.85% YoY) and the FY2025 annual result came in at $53.0 million, up 106.68% from the prior year.
• Total Current Liabilities fell to $41.7 million in Q1 2026 per PRLD's latest filing, from $53.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $53.0 million in Q4 2025 and troughed at $15.2 million in Q2 2023.
• A 5-year average of $23.0 million and a median of $20.9 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Current Liabilities dropped 21.65% in 2023, then surged 110.85% in 2026.
• Over 5 years, Total Current Liabilities stood at $21.7 million in 2022, then climbed by 0.59% to $21.8 million in 2023, then climbed by 17.46% to $25.6 million in 2024, then soared by 106.68% to $53.0 million in 2025, then decreased by 21.27% to $41.7 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $41.7 million, $53.0 million, and $18.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.